Advertisement

Topics

Bariatric Surgery and Pharmacokinetics of Lercanidipine

2018-04-20 09:47:10 | BioPortfolio

Published on BioPortfolio: 2018-04-20T09:47:10-0400

Clinical Trials [891 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension

The poupose of this study is to evaluate the efficacy and safety of various dosage combinations of lercanidipine (10 and 20 mg)and enalapril (10 and 20 mg) in comparison with their respect...

Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension

The purpose of this study is to evaluate the safety and efficacy of fixed combination of lercanidipine (10 mg or 20 mg) and valsartan (80 mg or 160 mg), lercanidipine and valsartan alone i...

Deep Brain Stimulation for Morbid Obesity

This is an open-label, phase I pilot trial designed to evaluate the safety and feasibility of deep brain stimulation (DBS) for the treatment of refractory morbid obesity. Patients with dia...

Bariatric Arterial Embolization for Morbid Obesity

The purpose of this study is to evaluate the safety and effectiveness of left gastric artery embolization(bariatric arterial embolization) for morbid obesity. When the target vessel is blo...

Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine

Human immunodeficiency virus infection and highly active antiretroviral therapy (HAART) are associated with an increased risk of cardiovascular disease: a wide range of alterations in lip...

PubMed Articles [2625 Associated PubMed Articles listed on BioPortfolio]

Lercanidipine and T-type calcium current.

Lercanidipine is a calcium antagonist with no cardiodepressant activity, long lasting antihypertensive action and reno-protective effect. Our previous data demonstrated that lercanidipine blocks L-typ...

Reliability of International Classification of Diseases, Ninth Edition, Codes to Detect Morbid Obesity in Patients Undergoing Total Hip Arthroplasty.

Although the impact of coding errors, with respect to obesity, has been previously reported, it is unclear whether morbid obesity is prone to similar coding inaccuracies. Therefore, the purpose of thi...

Is ICD-9 Coding of Morbid Obesity Reliable in Patients Undergoing Total Knee Arthroplasty?

Morbid obesity is considered to have a stronger association with complications after total knee arthroplasty (TKA). Although the impact of obesity coding errors has been previously reported, the exten...

Decrease of Plasma Soluble (Pro)renin Receptor by Bariatric Surgery in Patients with Obstructive Sleep Apnea and Morbid Obesity.

Plasma concentrations of soluble (pro)renin receptor [s(P)RR], which are elevated in patients with obstructive sleep apnea (OSA), have not been studied in morbid obesity. The aim of this study is to c...

Influence of Morbid Obesity and Bariatric Surgery Impact on the Carotid Adventitial Vasa Vasorum Signal.

Adventitial vasa vasorum (VV) expansion to the avascular intima precedes an increase in carotid intima-media thickness. However, factors involved in the development of the atherosclerotic process and ...

Medical and Biotech [MESH] Definitions

The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.

A status with BODY WEIGHT that is grossly above the acceptable or desirable weight, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Surgical procedures aimed at producing major WEIGHT REDUCTION in patients with MORBID OBESITY.

An inflatable device implanted in the stomach as an adjunct to therapy of morbid obesity. Specific types include the silicone Garren-Edwards Gastric Bubble (GEGB), approved by the FDA in 1985, and the Ballobes Balloon.

A procedure consisting of the SURGICAL ANASTOMOSIS of the proximal part of the JEJUNUM to the distal portion of the ILEUM, so as to bypass the nutrient-absorptive segment of the SMALL INTESTINE. Due to the severe malnutrition and life-threatening metabolic complications, this method is no longer used to treat MORBID OBESITY.

More From BioPortfolio on "Bariatric Surgery and Pharmacokinetics of Lercanidipine"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial